INTRODUCTION: With the arrival of the potent P2Y12 antagonists, ticagrelor and prasugrel,
the need for co-treatment with aspirin in acute coronary syndromes must be re-examined …

ÔDual antiplatelet therapyÕ, comprising aspirin and a P2Y12 receptor inhibitor, is firmly
established for the secondary prevention of thrombotic events with the rationale that they …

Background: Aspirin and antagonists of platelet ADP P2Y 12 receptors are often
coprescribed for protection against thrombotic events. However, blockade of platelet P2Y 12 …

Summary Background: Strong P2Y 12 blockade, as can be achieved with novel anti‐platelet
agents such as prasugrel, has been shown in vitro to inhibit both ADP and thromboxane A 2 …

Different aspirin dosing regimens have been suggested to impact outcomes when used in
combination with adenosine diphosphate (ADP) P2Y 12 receptor antagonists. Prior …

2 Tantry and Gurbel Aspirin Desensitization completed the desensitization protocol were
discharged on 100-mg aspirin per day, and 69.4% were on dual antiplatelet therapy. The …

The new P2Y 12 antagonist prasugrel produces greater inhibition of ADP-induced platelet
aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of …

Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with greater
pharmacodynamic inhibition and reduction of cardiovascular events in patients with an …

Aims P2Y 12 receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were
investigated in patients with stable coronary artery disease. Methods and results One …

INTRODUCTION: Off-target effects of novel antiplatelet agents due to their potential clinical
benefits are currently an area of intensive investigation. We aimed to compare the effects of …